← SynDRA
SOFOSBUVIR
SynDRA canonical compound SYN0024773 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | HCV inhibitor |
|---|
| Indication | hepatitis C |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- HCV inhibitor
- HCV NS5B MODULATOR
- NS5B INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP3A4
- ACHE
- PDE3A
- HTR2B
- KCNH2
- KDR
- MAOA
- OPRM1
- PDE4A
- HRH3
- PGR
- PTGS1
- SCN5A
- SLC6A2
- SLC6A3
- SLC6A4
- HTR1A
- F2
- ADORA3
- ESR1
- DRD3
- DRD1
- CYP2D6
- CYP2C9
- CYP1A2
- CTSA
- CHRM2
- CHRM1
- CES1
- CACNA1C
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Drug classes
- Anti-Infective Agents
- Antiviral Agents
- RNA Replicase Inhibitors
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- EPCLUSA
- Epclusa
- HARVONI
- Harvoni
- SOVALDI
- Sovaldi
- VOSEVI
- Vosevi
- sovaldi
- PSI-7977
- GS-7977
- GS7977
- Psi-7977, gs-7977
- Sofosbuvir component of epclusa
- Sofosbuvir component of harvoni
- Sofosbuvir component of vosevi
- PSI 7977
- GS 7977
- UNII-WJ6CA3ZU8B
- WJ6CA3ZU8B
- CHEBI:85083
- Sofosbuvir (PSI-7977, GS-7977)
- Hepcvir
- Hepcinat
- HSDB 8226
- Sofosbuvir [USAN:INN]
- Resof
- SoviHep
- Sovaldi (TN)
- Sofosbuvir (JAN/USAN)
- Sofosbuvir(PSI-7977)
- GTPL7368
- SCHEMBL2010114
- CHEMBL1259059
- AMMD00019
- EX-A389
- MolPort-028-720-482
Reported adverse events
- Bradycardia
- Angioedema
- Irritability
- Depression
- Asthenia
- Fatigue
- Headache
- Insomnia
- Nausea
- Rash
- Myalgia
- Vomiting
Look up SOFOSBUVIR in the interactive SynDRA portal →